adefovir

(redirected from Hepsera)
Also found in: Medical.
Related to Hepsera: Tyzeka
Translations

adefovir

n adefovir m
References in periodicals archive ?
Currently, Sigmapharm's product line consists of Adefovir Dipivoxil Tablets, for hepatitis B, which is the first and only generic product equivalent to Hepsera tablets; Sodium Phenylbutyrate Powder, for urea cycle disorders, which is equivalent to Buphenyl powder; Acitretin Capsules, which is equivalent to Soriatane capsules, with a primary indication for the treatment of severe psoriasis; and Liothyronine Sodium Tablets, for hypothyroidism, which is the most stable Liothyronine product on the market, with a recently Food and Drug Administration-approved shelf life of five years.
Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera.
In 2013, the global sales value of Hepsera was down by 23.
The multi-center, randomised, double-blind Phase III clinical studies compared Viread to Hepsera (adefovir dipivoxil) over 48 weeks, among both HBeAg-negative (study 102) and HBeAg-positive (study 103) chronic hepatitis B patients with compensated liver disease.
The company said it is cooperating in this civil and criminal investigation of Atripla, Emtriva, Hepsera, Letairis, Truvada, Viread and its investigational fixed-dose combination of Truvada and Edurant .
Revenue from other products, including the fungal infection treatment AmBisome, hepatitis B drug Hepsera, and Emtriva, an older HIV drug, slipped to $159.
The increase in Hepsera sales in the second quarter of 2008 compared to the same period of 2007 was driven primarily by a favorable foreign currency exchange impact and sales volume growth in certain European markets.
Food and Drug Administration cleared Hepsera for marketing in the United States in September 2002.
Currently, Sigmapharm's product line consists of Adefovir Dipivoxil Tablets, for hepatitis B, which is the first and only generic product equivalent to Hepsera tablets; Sodium Phenylbutyrate Powder, for urea cycle disorders, which is equivalent to Buphenyl powder; Liothyronine Sodium Tablets, for hypothyroidism, which is the most stable liothyronine product on the market, with a shelf life of 36 months and soon to be 48 months; and Acitretin Capsules (AB-rated to Soriatane capsules), with a primary indication for the treatment of severe psoriasis.
Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) said on Thursday that it has been notified that Sigmapharm Laboratories LLC has submitted an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA), seeking permission to manufacture and market a generic version of Hepsera (adefovir dipivoxil).
Other Sigmapharm releases include Liothyronine Sodium Tablets, for hypothyroidism, which is the most stable Liothyronine product on the market with a shelf life of 36 months; Adefovir Dipivoxil Tablets, for hepatitis B, which is the first and only generic product equivalent to Hepsera Tablets; and Sodium Phenylbutyrate Powder, for urea cycle disorders, which is the first and only generic product equivalent to Buphenyl Powder.
Other antiviral product sales, including Viread, Hepsera and Emtriva, were down 6% to $233.